N
TVRD

Nuveen’s Tvardi Therapeutics TVRD Stock Holding History

Nuveen’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,951
Closed -$232K – 3315
2025
Q3 		$232K Buy
+5,951
New +$169K ﹤0.01% 3118
2024
Q2 		– Sell
-3,165
Closed -$104K – 3435
2024
Q1 		$104K Hold
3,165
– – ﹤0.01% 3248
2023
Q4 		$84.7K Buy
3,165
+30
+1% +$1.24K ﹤0.01% 3294
2023
Q3 		$190K Sell
3,135
-42
-1% -$3.94K ﹤0.01% 3048
2023
Q2 		$324K Hold
3,177
– – ﹤0.01% 3004
2023
Q1 		$562K Sell
3,177
-368
-10% -$123K ﹤0.01% 2784
2022
Q4 		$1.37M Sell
3,545
-567
-14% -$215K ﹤0.01% 2546
2022
Q3 		$1.39M Sell
4,112
-312
-7% -$113K ﹤0.01% 2581
2022
Q2 		$1.45M Sell
4,424
-4,625
-51% -$1.62M ﹤0.01% 2606
2022
Q1 		$3.9M Sell
9,049
-63
-0.7% -$25.9K ﹤0.01% 2185
2021
Q4 		$3.86M Sell
9,112
-292
-3% -$147K ﹤0.01% 2260
2021
Q3 		$5.16M Sell
9,404
-7,253
-44% -$3.64M ﹤0.01% 2190
2021
Q2 		$8.56M Sell
16,657
-438
-3% -$278K ﹤0.01% 1962
2021
Q1 		$13.4M Buy
17,095
+6,680
+64% +$4.57M ﹤0.01% 1614
2020
Q4 		$5.67M Sell
10,415
-5,188
-33% -$2.72M ﹤0.01% 2001
2020
Q3 		$7.15M Buy
15,603
+1,638
+12% +$952K ﹤0.01% 1727
2020
Q2 		$8.6M Buy
13,965
+9,279
+198% +$5.12M ﹤0.01% 1584
2020
Q1 		$2.23M Sell
4,686
-9
-0.2% -$4.89K ﹤0.01% 2137
2019
Q4 		$2.72M Sell
4,695
-1,344
-22% -$943K ﹤0.01% 2299
2019
Q3 		$3.97M Buy
6,039
+2,423
+67% +$2.01M ﹤0.01% 2079
2019
Q2 		$2.8M Buy
+3,616
New +$2.54M ﹤0.01% 2268

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Nuveen's TVRD Position: Q4 2025 in Review

Nuveen sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 5,951 shares — an estimated $232K sold.

Nuveen first reported a position in TVRD in Q2 2019 and held it in 21 quarters. The position peaked at $13.4M in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • Nuveen reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nuveen sold 5,951 Tvardi Therapeutics shares in Q4 2025, an estimated $232K.
  • Nuveen first reported a position in Tvardi Therapeutics in Q2 2019 and held it in 21 quarters.
  • Nuveen's Tvardi Therapeutics position peaked at $13.4M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Nuveen's 13F filing for Q4 2025, filed 12 Feb 2026.